849671-56-3

Basic information

• Product Name: SPIRO[2.5]OCT-6-YL-METHANOL
• Synonyms: SPIRO[2.5]OCT-6-YL-METHANOL;Spiro[2.5]octan-6-ylMethanol;Spiro[2.5]octane-6-methanol
• CAS NO: 849671-56-3
• Molecular Formula: C₉H₁₆O
• Molecular Weight: 140.23
• Mol File: 849671-56-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: SPIRO[2.5]OCT-6-YL-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: SPIRO[2.5]OCT-6-YL-METHANOL(849671-56-3)
• EPA Substance Registry System: SPIRO[2.5]OCT-6-YL-METHANOL(849671-56-3)

Safety Data

• Hazardous Substances Data: 849671-56-3(Hazardous Substances Data)

Usage

General Description

SPIRO[2.5]OCT-6-YL-METHANOL, also known as spirooctanol, is a chemical compound with a spirocyclic structure consisting of an eight-membered ring and a methanol group. SPIRO[2.5]OCT-6-YL-METHANOL is commonly used in organic synthesis and medicinal chemistry as a building block for the preparation of various biologically active molecules. Its unique structure and functional groups make it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. Additionally, spirooctanol exhibits interesting physicochemical properties, making it an attractive candidate for the development of novel materials and catalysts. Overall, SPIRO[2.5]OCT-6-YL-METHANOL is a versatile compound with diverse applications in the fields of chemistry and material science.

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 75-11-6 diiodomethane 
• 1004-24-6 4-methylene-1-cyclohexanemethanol 
• 145576-28-9 ethyl 4-methylidenecyclohexanecarboxylate 

Downstream Products

• 1180557-35-0 C₁₆H₂₂O₃S 

Relevant articles and documents

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

We describe here orally active and brain-penetrant cathepsin S selective inhibitors, which are virtually devoid of hERG K+ channel affinity, yet exhibit nanomolar potency against cathepsin S and over 100-fold selectivity to cathepsin L. The new